Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia

There are five tyrosine kinase inhibitors (TKIs) that are currently approved (in the European Union and the United States) for the treatment of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of them has its own efficacy and toxicity profile. Oral ponatinib (Iclusig(®)) is a third...

Descripción completa

Detalles Bibliográficos
Autores principales: Molica, Matteo, Scalzulli, Emilia, Colafigli, Gioia, Foà, Robin, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399752/
https://www.ncbi.nlm.nih.gov/pubmed/30854182
http://dx.doi.org/10.1177/2040620719826444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399752/
https://www.ncbi.nlm.nih.gov/pubmed/30854182
http://dx.doi.org/10.1177/2040620719826444

Ejemplares similares